Browse All Grants
20,252 grants found
Showing 19,121 – 19,140 of 20,252 grants
Serial monitoring of circulating cell-free tumor DNA as measured by duplex sequencing in older patients with acute myeloid leukemia who receive azacitidine+venetoclax +/- immune checkpoint blockade
ABSTRACT IDH1 and IDH2 mutations are present in 15 to 20% of newly diagnosed cases of AML. They are associated with the production of the onco-metabolite 2-Hydroxyglutarate and a d...
Lactate production by tumor associated macrophages promotes tumorigenesis
ABSTRACT Tumor-associated macrophages (TAMs) are the most prevalent immune cell in the tumor microenvironment. TAMs adopt an M2-like phenotype that supports angiogenesis, attenuate...
Longitudinal Spatial-Nonspatial Decision Support for Competing Outcomes in Head and Neck Cancer Therapy
Project Summary/Abstract Head and neck cancer (HNC) patients survive years after oncologic therapy due to increased efficacy of therapy, increased incidences of human papilloma vir...
Langworthy Diversity Supplement: Image-based models of tumor-immune dynamics in glioblastoma
ABSTRACT Glioblastoma Multiforme (GBM) is the most common of all gliomas with a median survival 14-18 months, despite aggressive treatment regimens.Immunotherapy is emerging as a p...
Role of Sirt2 in T Cell Metabolism
PROJECT SUMMARY Metabolism is a key driver of T cell functions, and the switch from oxidative-phosphorylation to aerobic glycolysis is a hallmark of T cell activation. Unfortunatel...
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
PROJECT SUMMARY ABSTRACT High-risk resectable melanoma patients (MPs) with clinically detectable stage III with or without in-transit metastases have high-risk relapse1. Neoadjuvan...
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma
PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDA) is a lethal disease notoriously resistant to therapy including immune checkpoint blockade. Meanwhile, immunotherapy targeting...
Precision targeting of T cell cytotoxicity with PET
The recent clinical success of inhibitors against immune checkpoint proteins (e.g. CTLA-4, PD-L1), which are thought to stimulate T cell responses against tumors, has revolutionize...
Novel inhibitor for oncogenic RAS for lung cancer
Project Summary/Abstract: Aberrant activation of RAS signaling is a major driver of lung cancer resulting from gain-in-function mutations in RAS genes often caused by tobacco-deriv...
REGISTRATION, STORAGE AND DISTRIBUTION OF CHEMICALS AND DRUGS FOR PRE-CLINICAL DISCOVERY EVALUATION AND DEVELOPMENT
The Drug Synthesis and Chemistry Branch (DSCB) of the Developmental Therapeutics Program (DTP) of the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Insti...
Laboratory to Perform Assays of Coagulopathy Biomarkers for the National Cancer Institute’s COVID-19 in Cancer Patients Study (NCCAPS)
Lab will conduct coagulopathy assays for NCI to analyze as part of a correlative science objective in NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History...
Children's Oncology Group Statistics and Data Center
Administrative Supplement to Support Public Availability of Legacy COG Clinical Trial Data The NCTN/NCORP Data Archive serves as a repository of clinical trial data from phase 3 st...
Core A: Administration
ABSTRACT Core A will provide the leadership for scientific, administrative, fiscal, and organizational coordination of all the activities of the Projects and Cores to ensure this P...
BIOSPECIMEN PROCESSING CENTER (BPC) - EARLY ONSET MALIGNANCIES INITIATIVE
This Task Order provides support to the Early Onset Malignancies Initiative (EOMI).The EOMI is a collaborative initiative between CCG and the Division of Cancer Prevention?s NCI Co...
Multilevel investigation of uncertain and reclassified genomic variants in clinical oncology
PROJECT SUMMARY/ABSTRACT The overarching goal of this award is to prepare the applicant for an independent, sustained program of research that incorporates psychosocial, behavioral...
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma
PROJECT SUMMARY: Developing novel polytherapies for Non-Clear Cell Renal Carcinoma Non-clear cell renal cell carcinoma (NCCRCC) is the therapeutic outlier in kidney cancer because...
ROS-induced SPIO Targeted Platform for Transarterial Liver Cancer Therapy
Title: SPIO-GOx conjugate for transarterial liver cancer therapy Abstract: Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and ranks third amongst canc...
Novel inhibitor for oncogenic RAS for lung cancer
Project Summary/Abstract: Aberrant activation of RAS signaling is a major driver of lung cancer resulting from gain-in-function mutations in RAS genes often caused by tobacco-deriv...
A novel strategy to overcome drug resistance in cancer
ABSTRACT The major obstacle to successful cancer therapy is the rapid development of drug resistance. While targeted therapies often extend overall survival in the subset of patien...
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance
Abstract: Immunotherapy is becoming a pillar of cancer treatment, and many responsive patients have experienced durable, or even curative, outcomes. For reasons that remain unclear...